2023_May_Evonik_Eudracap_leaderboard

EXPERT VIEW

AUTOMATED LIPID NANOPARTICLE PRODUCTION: FROM PROTOCOL DEVELOPMENT TO GMP MANUFACTURE

AUTOMATED LIPID NANOPARTICLE PRODUCTION: FROM PROTOCOL DEVELOPMENT TO GMP MANUFACTURE

Richard Gray and Julia Rashba-Step discuss the benefits of automated lipid nanoparticle production.

OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY

OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY

Robert Lee discusses the growth of the ocular drug delivery market, the challenges formulators face in developing novel ocular technologies, and the role contract development and manufacturing organisations have to play in this growing market segment.

ADDRESSING ONGOING AND NEW BIOAVAILABILITY CHALLENGES

Dr Stephanie Emory

ADDRESSING ONGOING AND NEW BIOAVAILABILITY CHALLENGES

Stephanie Emory explores the pros and cons of various technologies for enhancing solubility and bioavailability for oral drug formulations. Further, Dr Emory draws on her experience as a reviewer at the US FDA to discuss how developers can view the FDA as a partner to aid success when leveraging innovative approaches.

ANALYTICAL TECHNIQUES FOR THE FORMULATION OF GASTRORETENTIVE TABLETS

ANALYTICAL TECHNIQUES FOR THE FORMULATION OF GASTRORETENTIVE TABLETS

Jamie Clayton, Phil Bone and Kyu Mok Hwang discuss the value of analyses such as mercury porosimetry and powder rheology in characterising excipients for gastroretentive tablet formulation, and go on to detail a case study investigating polymer excipients for a novel bilayer floating tablet.

THE POWER OF ONBOARDING: BUILDING PERSUASIVE USER EXPERIENCES FOR COMPANION APPS

THE POWER OF ONBOARDING: BUILDING PERSUASIVE USER EXPERIENCES FOR COMPANION APPS

Ben Cox discusses the value of onboarding in drug delivery device companion apps, and how it is a key component of converting a one-time user to a repeat user, unlocking the true value of companion apps as a tool for combating poor adherence to medications and gathering high-quality data.

ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION

Dr Andrew Donnelly

ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION

Andrew Donnelly and Shahid Uddin look at the challenges of self-administration of injectable viscous formulations and the technology that is helping to overcome these issues.

BIOCOMPATIBILITY OF MEDICINAL PRODUCT MEDICAL DEVICE COMBINATIONS FOR AIRWAY DELIVERY

BIOCOMPATIBILITY OF MEDICINAL PRODUCT MEDICAL DEVICE COMBINATIONS FOR AIRWAY DELIVERY

Mark Turner discusses biocompatibility testing for inhaled medical products, with particular reference to ISO 18562, and what Medical Engineering Technologies has learned from three years of breathing component biocompatibility testing.

NASAL DELIVERY: AN OPPORTUNITY FOR SIGNIFICANT IMPROVEMENTS IN PATIENT CARE

Dr Stuart Madden

NASAL DELIVERY: AN OPPORTUNITY FOR SIGNIFICANT IMPROVEMENTS IN PATIENT CARE

Stuart Madden discusses the advantages of the nasal route of administration for the systemic delivery of therapeutics.

FORMULATION OPTIONS IN NASAL DRUG DELIVERY

Dr Richard Johnson

FORMULATION OPTIONS IN NASAL DRUG DELIVERY

Richard Johnson discusses the advantages of nasal delivery and why there is growing interest in this route of administration, as well as considering some of the challenges that may arise during the development of nasal formulations for use in the clinic, and the regulatory and testing requirements associated with them.

CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT

CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT

Robert Lee discusses recent advances in ophthalmic dosage forms and how companies are meeting these challenges to better serve their customers.

DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES

Dr Suresh Gupta

DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES

Suresh Gupta discusses the challenges of developing a PFS product for intravitreal injection, highlighting how designing for the intravitreal space, rather than the standard parenteral, imposes a number of additional requirements on the design.

LINKING THE “D” & “M” IN CDMO

LINKING THE “D” & “M” IN CDMO

John Ross looks at the role of CDMOs in product development through to commercialisation and considers the benefits of consolidated “DM” models.

ROOM FOR INNOVATION?

ROOM FOR INNOVATION?

Darren Mansell examines US FDA guidance on biosimilar interchangeability and asks whether there is room for innovation.

TOP FIVE DRUG DELIVERY TRENDS FOR 2021

TOP FIVE DRUG DELIVERY TRENDS FOR 2021

Tom Oakley provides an overview of the top five trends to expect in drug delivery in 2021.

TACKLING PARENTERAL DRUG LABELLING’S SURGING COMPLEXITY

TACKLING PARENTERAL DRUG LABELLING’S SURGING COMPLEXITY

Lars Skole discusses emerging trends and challenges associated with growing parenteral packaging and labelling complexity – and how pharmaceutical developers and manufacturers can meet the challenges ahead.

CONNECTED DRUG DELIVERY: ACHIEVING OPTIMAL BENEFITS THROUGH SMART COLLABORATION

CONNECTED DRUG DELIVERY: ACHIEVING OPTIMAL BENEFITS THROUGH SMART COLLABORATION

George I’ons discusses the challenges developing connected devices presents to key market stakeholders when it comes to successful rollout and implementation. Additionally, he considers the perspectives of these market players, as well as the patients themselves, with respect to how connected drug delivery devices can help them to better achieve their desired outcomes.

ECONOMIC OPERATORS UNDER THE EU MDR: THE NEW REQUIREMENTS

ECONOMIC OPERATORS UNDER THE EU MDR: THE NEW REQUIREMENTS

Beth Crandall spells out the new requirements for Economic Operators under the EU Medical Device Regulation.

PREPARING FOR MASS VACCINATION

PREPARING FOR MASS VACCINATION

Andy Fry and Stephen Blatcher discuss the need for a mass vaccination device in response to the 2020 covid-19 pandemic. In particular, the authors discuss the benefits and challenges of turning to needle-free injection technology as a solution.

CONDUCTING EFFECTIVE AND INFORMATIVE EVALUATIONS OF INJECTION DEVICE PACKAGING

Allison Strochlic

CONDUCTING EFFECTIVE AND INFORMATIVE EVALUATIONS OF INJECTION DEVICE PACKAGING

Allison Strochlic and Andrea Dwyer discuss the often overlooked aspect of a combination product user interface: the packaging. With a specific look at injection devices, the authors cover how to perform proper human factors testing of a combination product’s packaging, and the advantages doing so can confer to a project.

SUSTAINABLE PHARMACEUTICALS CAN OUTPERFORM THROUGH NATURALLY DERIVED INGREDIENTS & DEEP EXPERTISE

SUSTAINABLE PHARMACEUTICALS CAN OUTPERFORM THROUGH NATURALLY DERIVED INGREDIENTS & DEEP EXPERTISE

Rina Chokshi discusses the benefits of naturally derived, sustainable ingredients and their benefits to the environment and pharmaceutical industry.

RETHINKING DRUG DELIVERY DEVICES FOR SUSTAINABILITY AND INNOVATION

RETHINKING DRUG DELIVERY DEVICES FOR SUSTAINABILITY AND INNOVATION

Sergio Malorni and George Bostock discuss the issue of designing for sustainability, including going beyond “Reduce, Reuse, Recycle” to “Rethink” and looking to adjacent and consumer industries for inspiration on innovations the drug delivery industry can adopt with a view to reducing its environmental impact.

SUSTAINABILITY AND DRUG DELIVERY DEVICES

SUSTAINABILITY AND DRUG DELIVERY DEVICES

Rob Veasey explores the environmental challenges facing the drug delivery device industry – and the opportunities they bring.

WEARABLE INJECTORS: LATEST DEVICES & RECENT TRENDS

WEARABLE INJECTORS: LATEST DEVICES & RECENT TRENDS

Wearable injection device expert Tom Oakley discusses recent trends in the space. He also takes a look at wearable injection devices currently on the market and considers the future of wearable injectors.

ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE

Frédérique Bordes-Picard

ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE

Frédérique Bordes-Picard and Julien Lamps discuss the value of capsule-based dry powder inhalers in the modern respiratory market, the factors driving development in this area and considerations for matching a capsule to a device and formulation.

THE RISE OF COMPLEX ORAL DELIVERY SYSTEMS

María Fernández-Martos Balson

THE RISE OF COMPLEX ORAL DELIVERY SYSTEMS

María Fernández-Martos Balson and Bastiaan De Leeuw explore the oral delivery of biologics and the challenges that must be overcome in order to enhance bioavailability. The authors also take a look at some recently developed drug-device combinations.

COVID-19: A CATALYST FOR IMPLEMENTING CONNECTED HEALTHCARE PRODUCTS?

Napoleon Monroe

COVID-19: A CATALYST FOR IMPLEMENTING CONNECTED HEALTHCARE PRODUCTS?

Napoleon Monroe analyses how covid-19 is catalysing a wide range of reactions in healthcare, explaining how drug and device connectivity are essential to improving patient access to treatment – and patient outcomes – as well as reducing overall cost.

RISKS AND REAL-WORLD SOLUTIONS FOR CONNECTED MEDICAL DEVICES

RISKS AND REAL-WORLD SOLUTIONS FOR CONNECTED MEDICAL DEVICES

Tom Oakley discusses the risks surrounding the use of connected drug delivery devices – and the real-world solutions that have either been proved or are being trialled.

CONNECTED DEVICE DATA NEEDED TO MAKE HOME CARE THE STANDARD

Dr Andrei Yosef

CONNECTED DEVICE DATA NEEDED TO MAKE HOME CARE THE STANDARD

With home care on the increase as a result of the coronavirus pandemic, Andrei Yosef looks at the crucial role played by connected home care medical devices and the data they generate.

SENSOR ADVANCEMENTS IN DRUG DELIVERY IMPROVE COMPLIANCE

Salvatore Forte

SENSOR ADVANCEMENTS IN DRUG DELIVERY IMPROVE COMPLIANCE

Salvatore Forte discusses various advancements in sensors that are transforming drug delivery systems, making complex devices more automated, easier to use, and improving patient compliance as a result.

WHICH IS THE BETTER TOXICITY TESTING STRATEGY FOR COMBINATION DEVICES?

WHICH IS THE BETTER TOXICITY TESTING STRATEGY FOR COMBINATION DEVICES?

Mark Turner explores the issue of toxicity testing for combination devices and asks which is the better testing strategy – ISO 10993 or extractables and leachables?

DESIGN CONSIDERATIONS FOR IMPROVING TRAINING DEVICE SAFETY AND EFFECTIVENESS

DESIGN CONSIDERATIONS FOR IMPROVING TRAINING DEVICE SAFETY AND EFFECTIVENESS

Yvonne Limpens and Brenda van Geel, explore the design considerations that need to be taken into account when developing training devices that are safe and effective – and support patients in learning how to administer an injection correctly.

EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?

EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?

With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.

SILICA RE-EMERGES AS POTENTIAL NUCLEIC ACID DELIVERY VECTOR

SILICA RE-EMERGES AS POTENTIAL NUCLEIC ACID DELIVERY VECTOR

Nigel Theobald looks at the challenges of oligonucleotide delivery and explores approaches to overcome them.

RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON

RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON

Brennan Miles takes a look back at respiratory drug delivery over the last few decades to see what we can learn from the past – and looks ahead to what the future might look like, covering sustainability, device regulation, and formulation milestones.

PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS

PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS

Igor Gonda, David Cipolla and Philippe Rogueda discuss the changes needed to increase the number of approved generic orally inhaled drug products (OIDPs) whilst providing additional incentives to innovators to meet the needs of the general public.

THE OPTIONS FOR CREATING A MORE SUSTAINABLE INHALER

THE OPTIONS FOR CREATING A MORE SUSTAINABLE INHALER

With growing pressure to tackle climate change, Phil Seeney looks at the arguments in favour of creating more sustainable inhalers, and examines potential strategies to accomplish it.

Prev
1
2
3
4
5
…
7
Next

Top